Macro­Gen­ics scores first FDA ap­proval with breast can­cer med Mar­gen­za in third-line pa­tients

In the sus­tain­ably hot on­col­o­gy field, breast can­cer has at­tract­ed some of the biggest play­ers on the mar­ket, in­clud­ing block­buster meds from Roche and Mer­ck. Now, a new play­er has tak­en the field af­ter the FDA gave a thumbs-up to new­com­er Macro­Gen­ics and its HER2 ex­press­ing tu­mor fight­er.

Macro­Gen­ics $MGNX scored its first FDA ap­proval Wednes­day for Mar­gen­za (mar­ge­tux­imab-cmkb) to treat metasta­t­ic HER2-pos­i­tive breast can­cer pa­tients who have al­ready re­ceived two or more pri­or HER2 reg­i­mens, in­clud­ing at least one in the metasta­t­ic set­ting, the Mary­land biotech said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.